Dr. Mukherjee on the Implications of the FDA Approval of Second-line Liso-cel in LBCL
Akash Mukherjee, MD, discusses the implications of the FDA approval of lisocabtagene maraleucel in large B-cell lymphoma.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
2 Clarke Drive Cranbury, NJ 08512